🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

RecruitingPhase 2, Phase 3Ages 21 Years - 80 YearsAllNational University of Singapore
NCT07282041 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. The investigators believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA). In this open label randomised clinical trial, patients with recently symptomatic and severe stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA) with impaired cerebral vasodilatory reserve (CVR) will be included. CVR will be measured with transcranial Doppler (TCD) breath holding index and acetazolamide-challenged single photon emission computed tomography (SPECT). Patients meeting the eli

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients aged 21 - 80 years old inclusive, * Able to provide consent, * Score 3 or less on the Modified Rankin Score (mRS), * Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA Exclusion Criteria: * Chronic kidney disease stage 5 (eGFR\<15 mL/min) or on dialysis, * Cancer diagnosed within past 3 years, * Currently being planned for coronary or carotid artery revascularization, * History of previous pancreatitis, * History of medullary thyroid cancer, * Atrial fibrillation, * Any other condition likely to limit protocol compliance (judged by investigator). * For diabetic patients, patients should not be on Sodium-glucose cotransporter 2 (SGLT2) inhibitor or pioglitazone during the duration of the study, unless these drugs can be stopped without affecting participants' medical condition. For those on Dipeptidyl peptidase-4 (DPP IV) inhibitor, this agent will be discontinued if the patient is randomised to the intervention group. * Known allergies to Acetazolamide. * Women who are pregnant or breastfeeding.
💊

What it tests

  • Dulaglutide
📍

Where

1 site
National University Hospital
Singapore, Singapore
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy